IFNG and Other metabolic disease: Two thirds of patients with negative control failures presented with concurrent hepatic dysfunction, which may stem from disease-associated systemic inflammation promoting nonspecific IFN-γ secretion - a phenomenon also documented in patients with malignancies, active TB, or metabolic disorders including hypertension and diabetes [25–27].